Literature DB >> 29935904

PD-1 immunobiology in autoimmune hepatitis and hepatocellular carcinoma.

Colleen S Curran1, Elad Sharon2.   

Abstract

Disruption of liver immune tolerance allows for the development of autoimmune hepatitis (AIH) and hepatocellular carcinoma (HCC). AIH rarely progresses to HCC but the diseases similarly induce the production of IL-18 and matrix metalloproteinases. These molecules have distinct effects on the immune response, including the programmed cell-death 1 (PD-1) axis. In this review, differences in PD-1 function and possible cell signals in AIH and HCC are highlighted. Published by Elsevier Inc.

Entities:  

Keywords:  IL-18; autoimmune hepatitis; hepatocellular carcinoma; matrix metalloproteinases; programmed cell-death 1 (PD-1)

Mesh：

Substances：

Year:  2018        PMID： 29935904      PMCID： PMC6086388          DOI： 10.1053/j.seminoncol.2017.12.001

Source DB:  PubMed          Journal:  Semin Oncol        ISSN： 0093-7754            Impact factor:   4.929


  72 in total

1.  PD-1hi Identifies a Novel Regulatory B-cell Population in Human Hepatoma That Promotes Disease Progression.

Authors:  Xiao Xiao; Xiang-Ming Lao; Min-Min Chen; Rui-Xian Liu; Yuan Wei; Fang-Zhu Ouyang; Dong-Ping Chen; Xiao-Yu Zhao; Qiyi Zhao; Xue-Feng Li; Chuan-Lu Liu; Limin Zheng; Dong-Ming Kuang
Journal:  Cancer Discov       Date:  2016-02-29       Impact factor: 39.397

2.  Serum and urinary levels of IL-18 and its inhibitor IL-18BP in systemic lupus erythematosus.

Authors:  Paola Migliorini; Consuelo Anzilotti; Federico Pratesi; Paola Quattroni; Marco Bargagna; Charles A Dinarello; Diana Boraschi
Journal:  Eur Cytokine Netw       Date:  2010-12-03       Impact factor: 2.737

3.  Role played by the programmed death-1-programmed death ligand pathway during innate immunity against Mycobacterium tuberculosis.

Authors:  Ivana B Alvarez; Virginia Pasquinelli; Javier O Jurado; Eduardo Abbate; Rosa M Musella; Silvia S de la Barrera; Verónica E García
Journal:  J Infect Dis       Date:  2010-08-15       Impact factor: 5.226

4.  A matrix metalloproteinase-9 activation cascade by hepatic stellate cells in trans-differentiation in the three-dimensional extracellular matrix.

Authors:  Yuan-Ping Han; Chunli Yan; Ling Zhou; Lan Qin; Hidekazu Tsukamoto
Journal:  J Biol Chem       Date:  2007-02-23       Impact factor: 5.157

Review 5.  Matrix metalloproteinase-9 and autoimmune diseases.

Authors:  Maya Ram; Yaniv Sherer; Yehuda Shoenfeld
Journal:  J Clin Immunol       Date:  2006-05-02       Impact factor: 8.317

6.  Autoimmune liver disease: overlap and outliers.

Authors:  Mary K Washington
Journal:  Mod Pathol       Date:  2007-02       Impact factor: 7.842

7.  PD-1 expression on dendritic cells suppresses CD8+ T cell function and antitumor immunity.

Authors:  Tong Seng Lim; Valerie Chew; Je Lin Sieow; Siting Goh; Joe Poh-Sheng Yeong; Ai Ling Soon; Paola Ricciardi-Castagnoli
Journal:  Oncoimmunology       Date:  2015-08-31       Impact factor: 8.110

8.  Axl activates autocrine transforming growth factor-β signaling in hepatocellular carcinoma.

Authors:  Patrick Reichl; Mirko Dengler; Franziska van Zijl; Heidemarie Huber; Gerhard Führlinger; Christian Reichel; Wolfgang Sieghart; Markus Peck-Radosavljevic; Markus Grubinger; Wolfgang Mikulits
Journal:  Hepatology       Date:  2015-01-28       Impact factor: 17.425

9.  Interleukin-37 mediates the antitumor activity in hepatocellular carcinoma: role for CD57+ NK cells.

Authors:  Jing-Jing Zhao; Qiu-Zhong Pan; Ke Pan; De-Sheng Weng; Qi-Jing Wang; Jian-Jun Li; Lin Lv; Dan-Dan Wang; Hai-Xia Zheng; Shan-Shan Jiang; Xiao-Fei Zhang; Jian-Chuan Xia
Journal:  Sci Rep       Date:  2014-06-05       Impact factor: 4.379

10.  Interleukin-21 plays a critical role in the pathogenesis and severity of type I autoimmune hepatitis.

Authors:  Kazumichi Abe; Atsushi Takahashi; Hiromichi Imaizumi; Manabu Hayashi; Ken Okai; Yukiko Kanno; Hiroshi Watanabe; Hiromasa Ohira
Journal:  Springerplus       Date:  2016-06-18
View more
  7 in total

Review 1.  Programmed Cell Death Protein 1/Programmed Cell Death Protein Ligand 1 Immunosuppressants in Advanced Non-Small Cell Lung Cancer Research Progress in Treatment.

Authors:  Feng Li; Binchi Liao; Ting Wang; Tingting Qi; Yixin Wang
Journal:  Front Pharmacol       Date:  2022-06-16       Impact factor: 5.988

2.  The Possible Role of Interleukin (IL)-18 and Nitrous Oxide and Their Relation to Oxidative Stress in the Development and Progression of Breast Cancer.

Authors:  Mona Mohamed K El-Deeb; Heba Gaber El-Sheredy; Ayman Farouk Mohammed
Journal:  Asian Pac J Cancer Prev       Date:  2019-09-01

Review 3.  Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology.

Authors:  Isaure Vanmeerbeek; Jenny Sprooten; Dirk De Ruysscher; Sabine Tejpar; Peter Vandenberghe; Jitka Fucikova; Radek Spisek; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi; Abhishek D Garg
Journal:  Oncoimmunology       Date:  2020-01-09       Impact factor: 8.110

4.  Correlation analysis of RDM1 gene with immune infiltration and clinical prognosis of hepatocellular carcinoma.

Authors:  Chen Qiu; Zuyin Li; Wanyue Cao; Xiaoni Cai; Li Ye; Cheng Zhang; Yuefeng Ma; Xiaoliang Wang; Yulong Yang
Journal:  Biosci Rep       Date:  2021-09-30       Impact factor: 3.840

Review 5.  B cells in autoimmune hepatitis: bystanders or central players?

Authors:  Christoph Schultheiß; Silja Steinmann; Ansgar W Lohse; Mascha Binder
Journal:  Semin Immunopathol       Date:  2022-04-29       Impact factor: 11.759

6.  PD-1 inhibitors plus lenvatinib versus PD-1 inhibitors plus regorafenib in patients with advanced hepatocellular carcinoma after failure of sorafenib.

Authors:  Yongkang Xu; Shumin Fu; Kai Shang; Jiayu Zeng; Ye Mao
Journal:  Front Oncol       Date:  2022-09-13       Impact factor: 5.738

Review 7.  PD-1 immunobiology in glomerulonephritis and renal cell carcinoma.

Authors:  Colleen S Curran; Jeffrey B Kopp
Journal:  BMC Nephrol       Date:  2021-03-06       Impact factor: 2.388
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.